title: Influence of corneal cross-linking for keratoconus on several objective parameters of dry eye.
abstract: OBJECTIVE
  To evaluate the potential influence of corneal cross-linking (CXL) with ultraviolet-A light and riboflavin in keratoconic eyes on several objective parameters of dry eye syndrome.
  
  
  METHODS
  This prospective single center study included 30 consecutive eyes of 16 patients that underwent CXL with riboflavin and ultraviolet-A treatment (epithelial removal, 30 minutes soaking with riboflavin, 30 minutes of illumination with 365 nm, 3 mW/cm(2), 5 cm distance). Several dry eye syndrome parameters were evaluated preoperatively and 3 and 6 months after the procedure: intra-individual comparison of fluorescein and Rose bengal staining, height of tear film meniscus, and tear film break-up time.
  
  
  RESULTS
  Pathologic staining (more than 10 point-shaped areas or diffuse staining) with fluorescein was evident before CXL in 1 eye, 3 months after CXL in 1 eye, and 6 months after CXL in 1 eye. Rose bengal staining 3 and 6 months postoperatively was comparable to preoperative staining. Tear film height was reduced in 2 eyes before CXL and in 4 eyes 3 months postoperatively, and was normal in all eyes after 6 months. The number of eyes with reduced tear film break-up time was not significantly changed.
  
  
  CONCLUSIONS
  CXL had no significant impact on several parameters of dry eye syndrome 3 and 6 months postoperatively.
authors.affiliation: Eye Department, St. Francis Hospital, Muenster, Germany. taneri@refraktives-zentrum.de
authors.forename: Suphi
authors.initials: S
authors.lastname: Taneri
authors.forename: Saskia
authors.initials: S
authors.lastname: Oehler
authors.forename: George
authors.initials: G
authors.lastname: Asimellis
authors.forename: A John
authors.initials: AJ
authors.lastname: Kanellopoulos
mesh_terms: D000328:Adult; D019781:Corneal Topography; D003432:Cross-Linking Reagents / Q000627:therapeutic use*; D015352:Dry Eye Syndromes / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007640:Keratoconus / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use; D011446:Prospective Studies; D012256:Riboflavin / Q000627:therapeutic use*; D016896:Treatment Outcome; D014466:Ultraviolet Rays; D014792:Visual Acuity; D055815:Young Adult
chemical_list: D003432:Cross-Linking Reagents; D017319:Photosensitizing Agents; D012256:Riboflavin